Treatment of patients w/ epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination w/ irinotecan-based chemotherapy or continuous infusional 5-FU/folinic acid + oxaliplatin; monotherapy in patients who have failed oxaliplatin- & irinotecan-based therapy & who are intolerant to irinotecan. Treatment of patients w/ squamous cell cancer of the head & neck in combination w/ radiation therapy for locally advanced disease; platinum-based chemotherapy for recurrent &/or metastatic disease.
Administer antihistamine & corticosteroid as premed prior to therapy. Initially 400 mg/m2 BSA once a wk by IV infusion for 120 min. Subsequently 250 mg/m2 wkly by IV infusion for 60 min. Max infusion rate: 10 mg/min.
View Erbitux overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity. Patients w/ mutant RAS metastatic colorectal cancer (mCRC) or for whom RAS mCRC status is unknown. Concomitant use of chemotherapeutics or radiation therapy.
Manage Account
Change Password
Sign Out
